Jan 16, 2020 / 04:30PM GMT
Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 health care conference today with Halozyme.
We're going to host a Q&A session with the management team right after this presentation. It's just down the hall in the Yorkshire Room. So come to that if you want to hear more. But for the presentation, I'm going to turn it over to the company's CEO, Helen Torley.
Helen I. Torley - Halozyme Therapeutics, Inc. - President, CEO & Director
Thank you, Jess, and thank you, everybody, for joining us today. In November 2019, after the negative data on PEGPH20, we rapidly transitioned Halozyme to become an ENHANZE-only company, focusing on our ENHANZE business. We rapidly restructured the company, reducing our expense base. And I'm very pleased to announce that 2020 will be our first year of sustainable profitability, with a projection of earnings per share of $0.60 to $0.75 in 2020. And this is just the
Halozyme Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers